

# Clinical and Molecular Characteristics Associated With With Checkpoint Inhibitors for Advanced Non-“Small

JAMA Oncology

4, 210

DOI: [10.1001/jamaoncol.2017.4427](https://doi.org/10.1001/jamaoncol.2017.4427)

Citation Report

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. <i>Cancer Treatment Reviews</i> , 2018, 64, 21-29.                  | 7.7  | 37        |
| 2  | ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?. <i>Lancet Oncology</i> , The, 2018, 19, 438-439.  | 10.7 | 5         |
| 3  | Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.  | 3.0  | 17        |
| 4  | Lung cancer in never smokers—the East Asian experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 450-463.   | 2.8  | 104       |
| 5  | Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.   | 2.8  | 8         |
| 6  | Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?. <i>Translational Lung Cancer Research</i> , 2018, 7, S370-S372.          | 2.8  | 2         |
| 7  | Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.    | 1.4  | 57        |
| 8  | Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.  | 1.4  | 42        |
| 9  | PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S287-S289.  | 2.8  | 4         |
| 10 | Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S312-S317.                 | 2.8  | 1         |
| 11 | Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S290-S293.  | 2.8  | 2         |
| 12 | Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7529-7542.              | 2.0  | 29        |
| 13 | Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. , 2018, 6, 155. |      | 82        |
| 14 | Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2857-2873.          | 4.3  | 10        |
| 15 | Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386.   | 4.3  | 15        |
| 16 | Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.   | 1.1  | 78        |
| 17 | Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.   | 7.7  | 37        |
| 18 | Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.                 | 7.1  | 567       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 362, k3529.   | 2.3  | 354       |
| 20 | PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. <i>Annals of Oncology</i> , 2018, 29, 2085-2091.                           | 1.2  | 221       |
| 21 | <i>TP53</i> , <i>STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.       | 7.0  | 257       |
| 22 | Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.               | 5.9  | 219       |
| 23 | Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. <i>Cancers</i> , 2018, 10, 248.   | 3.7  | 258       |
| 24 | Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018, 14, 2415-2431.                                | 2.4  | 24        |
| 25 | Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.  |      | 111       |
| 26 | Current and future developments of immunotherapy in lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 122-131.  | 0.5  | 1         |
| 27 | Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology</i> , The, 2018, 19, e374.  | 10.7 | 3         |
| 28 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.                               | 7.1  | 388       |
| 29 | KRAS: Reasons for optimism in lung cancer. <i>European Journal of Cancer</i> , 2018, 99, 20-27.  | 2.8  | 43        |
| 30 | Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. <i>JAMA Oncology</i> , 2018, 4, 1137.   | 7.1  | 1         |
| 31 | Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis—Reply. <i>JAMA Oncology</i> , 2018, 4, 1138.   | 7.1  | 2         |
| 32 | Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma. <i>International Journal of Cancer</i> , 2019, 144, 169-177.  | 5.1  | 9         |
| 33 | Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.  |      | 49        |
| 34 | Sequencing therapies in oncogene-driven non-small-cell lung cancer: how to get the best mileage?. <i>Future Oncology</i> , 2019, 15, 2899-2904.  | 2.4  | 1         |
| 35 | Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. <i>Translational Oncology</i> , 2019, 12, 1425-1431. | 3.7  | 21        |
| 36 | Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. <i>Current Oncology Reports</i> , 2019, 21, 84.                                   | 4.0  | 13        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. <i>Translational Lung Cancer Research</i> , 2019, 8, 286-301.   | 2.8  | 69        |
| 38 | Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.  | 2.4  | 4         |
| 39 | Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 2423-2433.  | 2.4  | 73        |
| 40 | Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 214-226.                                  | 2.8  | 66        |
| 41 | A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. <i>Internal Medicine</i> , 2019, 58, 3033-3037.                                 | 0.7  | 7         |
| 42 | Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 16-25. | 4.4  | 28        |
| 43 | Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.  | 3.7  | 35        |
| 44 | Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e196879.   | 5.9  | 161       |
| 45 | KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 951-954.   | 1.1  | 4         |
| 46 | Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. <i>Cancers</i> , 2019, 11, 923.  | 3.7  | 124       |
| 47 | A novel superhydrophobic coating consisting of SiC nanowires. <i>Materials Research Express</i> , 2019, 6, 105094.   | 1.6  | 3         |
| 48 | Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2218-2224.   | 1.9  | 27        |
| 49 | Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.                                | 3.6  | 15        |
| 50 | Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma. <i>Precision Cancer Medicine</i> , 0, 2, 5-5.  | 1.8  | 1         |
| 51 | Urinary NGAL and RBP Are Biomarkers of Normoalbuminuric Renal Insufficiency in Type 2 Diabetes Mellitus. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.   | 2.2  | 24        |
| 52 | The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987036.   | 3.2  | 45        |
| 53 | Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019, 18, 139.                             | 19.2 | 156       |
| 54 | New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. <i>Frontiers in Oncology</i> , 2019, 9, 953.   | 2.8  | 97        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis. <i>Immunotherapy</i> , 2019, 11, 311-320.   | 2.0  | 8         |
| 56 | EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1311-1320.   | 1.2  | 249       |
| 57 | Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.  | 4.5  | 38        |
| 58 | Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 195-197.   | 2.8  | 2         |
| 59 | Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2296.  | 4.1  | 35        |
| 60 | Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells. <i>Biochemistry</i> , 2019, 58, 2293-2296.  | 2.5  | 7         |
| 61 | <i>JAMA Oncology</i>â€™The Year in Review, 2018. <i>JAMA Oncology</i> , 2019, 5, 609.   | 7.1  | 0         |
| 62 | Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. <i>Cancers</i> , 2019, 11, 380.   | 3.7  | 33        |
| 63 | Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.   | 30.7 | 346       |
| 64 | Immunotherapy in Nonâ€™Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 4592-4602.  | 7.0  | 447       |
| 65 | KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.   | 6.1  | 142       |
| 66 | Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. <i>Scientific Reports</i> , 2019, 9, 4278.  | 3.3  | 26        |
| 67 | Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 87-103.  | 4.4  | 16        |
| 68 | <i>EGFR</i>-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.  | 1.6  | 286       |
| 69 | The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.   | 3.7  | 49        |
| 70 | Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 457-467.  | 3.1  | 7         |
| 71 | Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, S628-S632.   | 1.0  | 3         |
| 72 | Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. <i>Cancers</i> , 2019, 11, 1835. | 3.7  | 4         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S339-S342.   | 2.8  | 13        |
| 74 | KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.                                | 3.2  | 25        |
| 75 | RET rearranged non-small cell lung cancer and therapeutic implications. <i>Internal Medicine Journal</i> , 2019, 49, 1541-1545.  | 0.8  | 6         |
| 76 | Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S247-S264.                            | 2.8  | 59        |
| 77 | Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. <i>Nature Medicine</i> , 2019, 25, 111-118.   | 30.7 | 196       |
| 78 | Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. <i>Cancer Letters</i> , 2019, 442, 279-286.                                       | 7.2  | 34        |
| 79 | Recommendations for Ancillary Testing. , 2019, , 125-142.  |      | 0         |
| 80 | The Papanicolaou Society of Cytopathology System for Reporting Respiratory Cytology. , 2019, , .   |      | 9         |
| 81 | Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019, 120, 57-62.   | 6.4  | 68        |
| 82 | The impact of smoking on the effectiveness of immune checkpoint inhibitors – a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 96-100.   | 1.8  | 13        |
| 83 | The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. <i>Cancer Letters</i> , 2020, 470, 95-105. | 7.2  | 193       |
| 84 | The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. <i>Case Reports in Oncology</i> , 2020, 12, 765-776.                       | 0.7  | 9         |
| 85 | Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. <i>Anticancer Research</i> , 2020, 40, 427-433.  | 1.1  | 16        |
| 86 | Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. <i>Nanoscale</i> , 2020, 12, 413-436.  | 5.6  | 49        |
| 87 | RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102859.  | 4.4  | 12        |
| 88 | Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 375.   | 7.1  | 215       |
| 89 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 324-343.   | 1.1  | 34        |
| 90 | Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 106-113.e5.        | 2.6  | 22        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Tumour mutation burden of nonâ€small cell lung cancer with preâ€existing ILD. <i>Respirology</i> , 2020, 25, 784-786.  | 2.3 | 0         |
| 92  | Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients. <i>Annals of Palliative Medicine</i> , 2020, 9, 4446-4457.  | 1.2 | 5         |
| 93  | Immune checkpoint blockade and biomarkers of clinical response in nonâ€small cell lung cancer. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12980.   | 2.7 | 14        |
| 94  | Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. <i>Immunotherapy</i> , 2020, 12, 1195-1207.  | 2.0 | 2         |
| 95  | Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Nonâ€Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013770.   | 5.9 | 34        |
| 96  | Superior efficacy of immunotherapyâ€based combinations over monotherapy for EGFR â€mutant nonâ€small cell lung cancer acquired resistance to EGFRâ€TKIs. <i>Thoracic Cancer</i> , 2020, 11, 3501-3509.   | 1.9 | 9         |
| 97  | Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.   | 5.6 | 8         |
| 98  | <scp><i>KRAS</i></scp> oncogene may be another target conquered in <scp>nonâ€small</scp> cell lung cancer (<scp>NSCLC</scp>). <i>Thoracic Cancer</i> , 2020, 11, 3425-3435.  | 1.9 | 10        |
| 99  | The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.   | 2.8 | 47        |
| 100 | Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. <i>Oral Oncology</i> , 2020, 111, 105024.  | 1.5 | 7         |
| 101 | Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. <i>Frontiers in Immunology</i> , 2020, 11, 1479.  | 4.8 | 30        |
| 102 | Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.  | 3.2 | 49        |
| 103 | Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Nonâ€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e250-e254. | 2.6 | 4         |
| 104 | Short-Chain Fatty Acids: A Soldier Fighting Against Inflammation and Protecting From Tumorigenesis in People With Diabetes. <i>Frontiers in Immunology</i> , 2020, 11, 590685.   | 4.8 | 41        |
| 105 | Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report. <i>Annals of Palliative Medicine</i> , 2020, 9, 4339-4345.   | 1.2 | 2         |
| 106 | Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 818-822.  | 3.0 | 2         |
| 107 | KRAS inhibition in nonâ€small cell lung cancer: Past failures, new findings and upcoming challenges. <i>European Journal of Cancer</i> , 2020, 137, 57-68.   | 2.8 | 30        |
| 108 | B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 153134.   | 2.3 | 15        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Targeting PD-L1 in non-small cell lung cancer using CAR T cells. <i>Oncogenesis</i> , 2020, 9, 72.  | 4.9  | 48        |
| 110 | ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 10-16.  | 2.0  | 7         |
| 111 | A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. <i>Translational Lung Cancer Research</i> , 2020, 9, 1124-1137.   | 2.8  | 6         |
| 112 | &lt;p&gt;Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations&lt;/p&gt;. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 59-71.   | 2.7  | 0         |
| 113 | Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression. <i>Cancers</i> , 2020, 12, 2496.   | 3.7  | 11        |
| 114 | Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 602762.  | 2.8  | 59        |
| 116 | What Is the Standard First-Line Treatment for Advanced Nonâ€“Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 485-495.   | 2.0  | 5         |
| 117 | Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 517-524.  | 2.0  | 18        |
| 118 | Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. <i>Journal of Thoracic Disease</i> , 2020, 12, 5096-5103.  | 1.4  | 0         |
| 119 | PrÃazisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <i>Karger Kompass Pneumologie</i> , 2020, 8, 300-317.                                  | 0.0  | 1         |
| 120 | Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.   | 1.4  | 29        |
| 121 | Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 372-384.                                    | 3.8  | 64        |
| 122 | Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2020, 80, 883-892.   | 10.9 | 5         |
| 123 | Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.   | 3.7  | 43        |
| 124 | Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2699-2707. | 2.5  | 9         |
| 125 | Immuno-Oncologyâ€“The New Paradigm of Lung Cancer Treatment. <i>Current Oncology</i> , 2020, 27, 78-86.   | 2.2  | 18        |
| 126 | The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.           | 1.1  | 182       |
| 127 | Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2523-2532.   | 4.2  | 54        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 128 | Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.   | 2.1 | 3         |
| 129 | Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. <i>Journal of Clinical Oncology</i> , 2020, 38, 2926-2936.   | 1.6 | 107       |
| 130 | Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4325.   | 4.1 | 84        |
| 131 | Tobacco extracts promote <i>PD-L1</i> expression and enhance malignant biological differences via <i>mTOR</i> in gefitinib-resistant cell lines. <i>Thoracic Cancer</i> , 2020, 11, 2237-2251.   | 1.9 | 4         |
| 132 | Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. <i>Life Sciences</i> , 2020, 256, 117923.   | 4.3 | 21        |
| 133 | Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.  | 2.0 | 8         |
| 134 | Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2020, 12, 2859-2876.   | 1.4 | 11        |
| 135 | Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.   | 2.6 | 31        |
| 136 | Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.  | 1.1 | 119       |
| 137 | Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.  | 4.1 | 39        |
| 138 | Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100052.                                      | 1.1 | 9         |
| 139 | The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC. <i>Genes and Diseases</i> , 2022, 9, 245-251.   | 3.4 | 17        |
| 141 | Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations. <i>Current Treatment Options in Oncology</i> , 2020, 21, 60.  | 3.0 | 6         |
| 142 | Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor. <i>Anticancer Research</i> , 2020, 40, 3889-3896.  | 1.1 | 12        |
| 143 | Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment. <i>Frontiers in Oncology</i> , 2019, 9, 1556.   | 2.8 | 27        |
| 144 | Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, e536-e544.   | 3.7 | 39        |
| 145 | Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2037-2046.   | 7.0 | 142       |
| 146 | Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 207-217. | 2.8 | 21        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 147 | EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. <i>Oncogene</i> , 2020, 39, 2643-2657.   | 5.9  | 43        |
| 148 | Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 15.   | 1.9  | 58        |
| 149 | The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients'™ Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.  | 2.4  | 7         |
| 150 | Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. <i>Science China Life Sciences</i> , 2020, 63, 1499-1514.  | 4.9  | 20        |
| 151 | Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 101-106.  | 4.2  | 26        |
| 152 | The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 256-266. | 1.5  | 15        |
| 153 | Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 245-251.  | 2.5  | 47        |
| 154 | TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 451-459.   | 6.1  | 33        |
| 155 | Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 877-886.  | 0.9  | 3         |
| 156 | Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2021, 102, 397-411.  | 3.3  | 9         |
| 157 | The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.  | 10.5 | 102       |
| 158 | Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?. <i>Current Opinion in Oncology</i> , 2021, 33, 64-72.  | 2.4  | 3         |
| 159 | Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100297.  | 1.7  | 4         |
| 160 | The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas. <i>Diagnostics</i> , 2021, 11, 196.   | 2.6  | 24        |
| 161 | ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. <i>Theranostics</i> , 2021, 11, 3392-3416.  | 10.0 | 61        |
| 162 | Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100107.  | 1.1  | 15        |
| 163 | The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis. <i>Oncology</i> , 2021, 99, 271-279.  | 1.9  | 11        |
| 164 | Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. <i>Journal of Neuro-Oncology</i> , 2021, 152, 125-134.                                      | 2.9  | 7         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 165 | Checkpoint-Inhibitoren. Springer Reference Medizin, 2021, , 1-11.   | 0.0  | 0         |
| 166 | Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma. Targeted Oncology, 2021, 16, 189-196.  | 3.6  | 3         |
| 167 | Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 965-980.  | 2.8  | 12        |
| 168 | Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. International Journal of Molecular Sciences, 2021, 22, 2142.  | 4.1  | 6         |
| 169 | Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. International Journal of Clinical Oncology, 2021, 26, 1065-1072.              | 2.2  | 3         |
| 170 | CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 1231-1242.  | 1.1  | 16        |
| 171 | Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2021, 39, 1040-1091.   | 1.6  | 192       |
| 172 | PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharmaceutica Sinica B, 2021, 11, 3120-3133.  | 12.0 | 16        |
| 173 | Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Medicine, 2021, 10, 2216-2231.  | 2.8  | 48        |
| 174 | Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology, 2021, 11, 638360.  | 2.8  | 42        |
| 175 | Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. Critical Reviews in Oncology/Hematology, 2021, 159, 103225.                  | 4.4  | 10        |
| 176 | RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. European Journal of Cancer, 2021, 146, 74-83.   | 2.8  | 29        |
| 177 | Comprehensive tumor molecular profile analysis in clinical practice. BMC Medical Genomics, 2021, 14, 105.   | 1.5  | 10        |
| 178 | Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer. Cells, 2021, 10, 831.  | 4.1  | 12        |
| 179 | MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2021, 12, 625593.  | 3.5  | 7         |
| 180 | Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. Journal of Controlled Release, 2021, 332, 109-126. | 9.9  | 33        |
| 181 | Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. Journal of the National Cancer Institute, 2021, 113, 1634-1647.  | 6.3  | 28        |
| 182 | Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 591922.  | 2.8  | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 183 | Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 2959-2967.      | 1.4 | 2         |
| 184 | Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 35-50.   | 2.7 | 25        |
| 185 | KRAS G12C Mutant Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 507-520.   | 2.8 | 40        |
| 186 | PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. <i>Cell Reports</i> , 2021, 35, 109181.   | 6.4 | 27        |
| 187 | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 635007.  | 2.8 | 76        |
| 188 | Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. <i>Lung Cancer</i> , 2021, 155, 163-169.   | 2.0 | 23        |
| 189 | Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5649.   | 4.1 | 16        |
| 190 | Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. <i>BMC Cancer</i> , 2021, 21, 731.  | 2.6 | 4         |
| 191 | Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. <i>Annals of Translational Medicine</i> , 2021, 9, 1035-1035.   | 1.7 | 9         |
| 192 | Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2779-2787.  | 2.8 | 4         |
| 193 | Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.  | 1.1 | 79        |
| 194 | Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2736-2751.   | 2.8 | 7         |
| 195 | A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-11.          | 1.2 | 3         |
| 196 | The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 702924.                                  | 2.8 | 6         |
| 197 | Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy. <i>Journal of Neurosurgery</i> , 2022, 136, 56-66.   | 1.6 | 3         |
| 198 | Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. <i>Lung Cancer</i> , 2021, 156, 91-99. | 2.0 | 11        |
| 199 | Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers. <i>Frontiers in Oncology</i> , 2021, 11, 625668.  | 2.8 | 9         |
| 200 | The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 671127.  | 2.8 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 201 | Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. <i>Cancers</i> , 2021, 13, 3415.  | 3.7 | 15        |
| 202 | Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. <i>Scientific Reports</i> , 2021, 11, 14999.   | 3.3 | 5         |
| 203 | Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. <i>Translational Oncology</i> , 2021, 14, 101102.                           | 3.7 | 8         |
| 204 | Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1952-1958.   | 1.1 | 32        |
| 205 | Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 5939-5950.   | 7.0 | 21        |
| 206 | Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 15907.   | 3.3 | 14        |
| 207 | Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 719-726.  | 4.2 | 33        |
| 208 | Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma. <i>Disease Markers</i> , 2021, 2021, 1-8.  | 1.3 | 3         |
| 209 | Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. <i>Immunotherapy</i> , 2021, 13, 941-952.   | 2.0 | 14        |
| 210 | Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2078-2090. | 1.1 | 29        |
| 211 | Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1267-1288.   | 1.1 | 77        |
| 212 | Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 26-26.  | 1.8 | 1         |
| 213 | The Predictive Value of Clinical and Molecular Characteristics of Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.                | 2.8 | 11        |
| 214 | Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 2873-2885.                                      | 1.9 | 10        |
| 215 | Updates in the molecular pathology of non-small cell lung cancer. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 54-61.  | 1.5 | 10        |
| 216 | Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. <i>Biomarker Research</i> , 2021, 9, 69.   | 6.8 | 4         |
| 217 | Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 731429.   | 2.8 | 5         |
| 218 | Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a037895.   | 6.2 | 24        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 219 | Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.   | 12.8 | 19        |
| 220 | Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. <i>Genes and Diseases</i> , 2022, 9, 1181-1193.   | 3.4  | 8         |
| 221 | Updates and new entities in neoplastic lung diseases. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 53.  | 1.5  | 1         |
| 222 | Effect of different levels of PEEP on mortality in ICU patients without acute respiratory distress syndrome: systematic review and meta-analysis with trial sequential analysis. <i>Journal of Critical Care</i> , 2021, 65, 246-258.                        | 2.2  | 3         |
| 223 | Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1622-1626. | 1.1  | 4         |
| 224 | Immunotherapy in non-small cell lung cancer: update and new insights. <i>Journal of Clinical and Translational Research</i> , 0, , .   | 0.3  | 23        |
| 225 | Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.  | 28.4 | 141       |
| 226 | Ras and Ras Signaling as a Therapeutic Target in Cancer. , 2021, , .   |      | 0         |
| 227 | Lung cancer patients. , 2021, , 165-180.   |      | 1         |
| 228 | Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. <i>Translational Lung Cancer Research</i> , 2021, 10, 506-518.   | 2.8  | 49        |
| 229 | Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival. <i>Clinical Lung Cancer</i> , 2020, 21, e445-e455.   | 2.6  | 7         |
| 230 | Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.  | 12.8 | 140       |
| 231 | Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer. <i>Bioscience Reports</i> , 2020, 40, .   | 2.4  | 12        |
| 232 | KRASG12C inhibitor: combing for combination. <i>Biochemical Society Transactions</i> , 2020, 48, 2691-2701.  | 3.4  | 10        |
| 233 | Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 768-781.                           | 3.0  | 33        |
| 234 | Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?. <i>Annals of Translational Medicine</i> , 2019, 7, S32-S32.   | 1.7  | 1         |
| 235 | Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?. <i>Annals of Translational Medicine</i> , 2019, 7, S76-S76.   | 1.7  | 5         |
| 236 | Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer. <i>Translational Cancer Research</i> , 2018, 8, S55-S63.   | 1.0  | 12        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 237 | <p>Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study</p>. Lung Cancer: Targets and Therapy, 2020, Volume 11, 113-121.                                | 2.7 | 7         |
| 238 | Tumor immune microenvironment of <i>EGFR</i>-mutant non-small-cell lung cancer and its impact on therapeutic efficacy. Immunotherapy, 2020, 12, 431-437.  | 2.0 | 4         |
| 239 | Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients. Radiology and Oncology, 2019, 53, 453-458.   | 1.7 | 3         |
| 241 | Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. Cancer Research Statistics and Treatment, 2019, 2, 36.  | 0.6 | 23        |
| 242 | NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 574-578.   | 4.9 | 41        |
| 243 | Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma. Cell Death and Disease, 2021, 12, 935.  | 6.3 | 10        |
| 244 | MET Amplification and Efficacy of Nivolumab in Patients With NSCLC. JTO Clinical and Research Reports, 2021, 2, 100239.   | 1.1 | 4         |
| 245 | Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Modern Pathology, 2022, 35, 66-74.   | 5.5 | 33        |
| 246 | Liquid Biopsy to Characterize Cell-Free DNA in Cancer Detection and Monitoring. Research and Development on Information and Communication Technology, 2019, 2019, 93-98.  | 0.4 | 0         |
| 247 | Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. Journal of Immunotherapy and Precision Oncology, 2020, 3, 121-127.   | 1.4 | 1         |
| 248 | Expression of MiR-608 in Nonsmall Cell Lung Cancer and Molecular Mechanism of Apoptosis and Migration of A549 Cells. BioMed Research International, 2020, 2020, 1-8.  | 1.9 | 7         |
| 249 | Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research, 2020, 2020, 1-11. | 2.2 | 8         |
| 250 | Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutationâ€“positive nonâ€“small-cell lung cancer in a real-world setting (OSI-FACT). European Journal of Cancer, 2021, 159, 144-153.                                      | 2.8 | 33        |
| 251 | Immunotherapy strategy of EGFR mutant lung cancer. American Journal of Cancer Research, 2018, 8, 2106-2115.   | 1.4 | 18        |
| 255 | Immunotherapy in non-small cell lung cancer: Update and new insights. Journal of Clinical and Translational Research, 2021, 7, 1-21.  | 0.3 | 16        |
| 256 | PDâ€“1<sup>+</sup>CXCR5<sup>+</sup>CD4<sup>+</sup> T cells are correlated with the severity of lung adenocarcinoma malignant processes. Scandinavian Journal of Immunology, 2022, 95, .   | 2.7 | 0         |
| 257 | Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 782106.  | 4.8 | 0         |
| 258 | Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. Frontiers in Oncology, 2021, 11, 739090.  | 2.8 | 19        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 259 | STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. <i>Cells</i> , 2021, 10, 3129.   | 4.1 | 30        |
| 260 | B7-4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. <i>Oncogene</i> , 2022, 41, 704-717.   | 5.9 | 15        |
| 261 | Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. <i>Frontiers in Oncology</i> , 2021, 11, 750657.   | 2.8 | 32        |
| 262 | Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1994-1998.  | 1.1 | 7         |
| 263 | Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.   | 1.6 | 5         |
| 264 | Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 15-24.  | 2.1 | 2         |
| 265 | Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.  | 1.1 | 9         |
| 266 | Targeting KRAS in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 792635.  | 2.8 | 17        |
| 267 | Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 162, 1-10. | 2.8 | 14        |
| 268 | Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 386-393.  | 1.9 | 8         |
| 269 | Effects of Different Factors on the Efficacy of Anti PD-(L)1 Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer: An Observational, Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4 | 0         |
| 270 | Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. <i>Cancer</i> , 2022, 128, 1574-1583.  | 4.1 | 14        |
| 271 | Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.   | 1.6 | 242       |
| 272 | Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. <i>Oncology and Therapy</i> , 2022, 10, 291-300.       | 2.6 | 1         |
| 273 | The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 834142.   | 4.8 | 4         |
| 274 | ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). <i>Lung Cancer</i> , 2022, 165, 54-62. | 2.0 | 6         |
| 275 | The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. <i>PLoS ONE</i> , 2022, 17, e0263247.  | 2.5 | 8         |
| 276 | Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.   | 4.8 | 105       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 277 | Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12C” Patients. <i>Cancers</i> , 2021, 13, 6332.   | 3.7 | 10        |
| 278 | The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2021, 28, 5408-5421.  | 2.2 | 2         |
| 279 | Research progress in immunotherapy of NSCLC with EGFR sensitive mutations. <i>Oncology Research</i> , 2022, , .   | 1.5 | 0         |
| 280 | Salvage Therapy of Osimertinib Plus Anlotinib in Advanced Lung Adenocarcinoma with Leptomeningeal Metastasis: A Case Report. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4 | 0         |
| 281 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487.  | 1.2 | 67        |
| 282 | Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients. <i>Annals of Translational Medicine</i> , 2022, 10, 214-214.  | 1.7 | 1         |
| 283 | Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience. <i>Frontiers in Immunology</i> , 2022, 13, 832419.                | 4.8 | 11        |
| 284 | Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 820408.     | 2.8 | 1         |
| 285 | A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS mutant invasive non-mucinous adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 1050-1058. | 1.9 | 5         |
| 286 | Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1429.   | 2.4 | 12        |
| 287 | KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 831382.   | 3.5 | 8         |
| 288 | Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer. <i>Siberian Journal of Oncology</i> , 2022, 21, 115-121.   | 0.3 | 1         |
| 289 | Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1627.  | 2.4 | 14        |
| 290 | Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1855.  | 2.4 | 11        |
| 291 | Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.  | 2.8 | 32        |
| 292 | The prevalence and real-world therapeutic analysis of Chinese patients with KRAS Mutant Non-Small Cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 3581-3592.   | 2.8 | 10        |
| 293 | Histologic transformation of epidermal growth factor receptor-mutated lung cancer. <i>European Journal of Cancer</i> , 2022, 166, 41-50.  | 2.8 | 10        |
| 294 | Clinical tissue biomarker digital image analysis: A review of current applications. <i>Human Pathology Reports</i> , 2022, 28, 300633.  | 0.3 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 295 | Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study. <i>Cancers</i> , 2022, 14, 93.   | 3.7 | 7         |
| 296 | What is the current role of immunotherapy in EGFR mutant advanced NSCLC?. <i>Lung Cancer</i> , 2021, , .  | 2.0 | 0         |
| 297 | Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 11419-11424.  | 0.8 | 1         |
| 298 | Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.   | 7.2 | 38        |
| 300 | A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 788837.  | 2.8 | 1         |
| 301 | The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 213-223.                                 | 2.8 | 6         |
| 302 | Limited role of <i>KRAS</i> mutation in guiding immunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 2433-2443.   | 2.4 | 2         |
| 305 | Research progress in immune checkpoint inhibitors in the treatment of oncogenedriven advanced nonsmall cell lung cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2020, 45, 418-425.   | 0.1 | 0         |
| 309 | Current Status and Prospects of Perioperative Treatment with Immune Checkpoint Inhibitors for Resectable Non-Small Cell Lung Cancer. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 83-86.   | 0.0 | 0         |
| 310 | Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. <i>Clinical Lung Cancer</i> , 2022, 23, 477-486.  | 2.6 | 10        |
| 311 | Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review. <i>Translational Lung Cancer Research</i> , 2022, 11, 920-934.   | 2.8 | 6         |
| 312 | Three Cases of <i>EGFR</i> -mutated Lung Cancer That Transformed to Small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 107-114.   | 0.1 | 1         |
| 314 | Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2613.   | 3.7 | 8         |
| 315 | Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. <i>Cancers</i> , 2022, 14, 2519.  | 3.7 | 8         |
| 316 | Sesquiterpene from <i>Polygonum barbatum</i> disrupts mitochondrial membrane potential to induce apoptosis and inhibits metastasis by downregulating matrix metalloproteinase and osteopontin in NCI-H460 cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , . | 3.0 | 0         |
| 317 | Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-14.  | 1.3 | 2         |
| 318 | The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, , .  | 2.8 | 4         |
| 319 | Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. <i>Translational Lung Cancer Research</i> , 2022, 11, 964-974.  | 2.8 | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 320 | PD-1 Blockade Plus Chemotherapy for EGFR-Mutant, EGFR Tyrosine Kinase Inhibitor-Pretreated Non-Small Cell Lung Cancer: A Multicenter Retrospective Study on Efficacy and Biomarker Exploration. SSRN Electronic Journal, 0, , .           | 0.4 | 0         |
| 321 | Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1755-1763. | 2.5 | 5         |
| 322 | Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Frontiers in Immunology, 0, 13, .   | 4.8 | 3         |
| 323 | Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report. Respiratory Medicine Case Reports, 2022, , 101682.   | 0.4 | 1         |
| 324 | A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib. BMC Medical Genomics, 2022, 15, .   | 1.5 | 1         |
| 325 | A predictive model based on liquid biopsy for non-small cell lung cancer to assess patient's prognosis: Development and application. Tissue and Cell, 2022, 77, 101854.   | 2.2 | 1         |
| 326 | Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease. Drugs in Context, 0, 11, 1-10.   | 2.2 | 1         |
| 327 | A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report. Frontiers in Oncology, 0, 12, .              | 2.8 | 1         |
| 328 | Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. Frontiers in Immunology, 0, 13, .  | 4.8 | 11        |
| 329 | <i>KRAS</i> G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Communications, 2022, 42, 828-847.  | 9.2 | 29        |
| 330 | Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Clinical Lung Cancer, 2022, 23, 571-577.   | 2.6 | 8         |
| 331 | A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. Journal of Translational Medicine, 2022, 20, .  | 4.4 | 7         |
| 332 | Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Frontiers in Immunology, 0, 13, .   | 4.8 | 5         |
| 333 | Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. International Journal of Molecular Sciences, 2022, 23, 8541.   | 4.1 | 2         |
| 334 | Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers in Oncology, 0, 12, .  | 2.8 | 32        |
| 335 | A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORIG1630. Clinical Cancer Research, 2022, 28, 4402-4409.                            | 7.0 | 11        |
| 336 | Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer. JCI Insight, 2022, 7, .  | 5.0 | 35        |
| 337 | Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Frontiers in Oncology, 0, 12, .   | 2.8 | 4         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 338 | EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3943.  | 3.7  | 9         |
| 339 | Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .  | 4.8  | 1         |
| 340 | A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2022, 11, 1619-1630. | 2.8  | 3         |
| 341 | Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 1151-1164.   | 13.2 | 79        |
| 342 | Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma (Review). <i>Oncology Letters</i> , 2022, 24, .   | 1.8  | 16        |
| 343 | Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1021-1032.                                      | 2.0  | 1         |
| 344 | A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100416.  | 1.1  | 1         |
| 345 | Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. <i>Frontiers in Immunology</i> , 0, 13, .   | 4.8  | 4         |
| 346 | Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report. <i>Lung Cancer</i> , 2022, 174, 186-187.  | 2.0  | 2         |
| 347 | The Interaction of the IFN $\gamma$ /JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-16.   | 1.3  | 1         |
| 348 | Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene. <i>Targeted Oncology</i> , 2022, 17, 683-694.  | 3.6  | 1         |
| 349 | Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1936-1950.   | 2.8  | 0         |
| 350 | The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100427.                     | 1.1  | 3         |
| 351 | Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives. <i>Cells</i> , 2022, 11, 3200.  | 4.1  | 15        |
| 352 | Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. <i>Trends in Cancer</i> , 2023, 9, 42-54.   | 7.4  | 13        |
| 353 | Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. <i>Cancer Communications</i> , 2023, 43, 42-74.  | 9.2  | 9         |
| 354 | The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. <i>Cancer Letters</i> , 2022, 551, 215947.  | 7.2  | 1         |
| 355 | Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211353.                                    | 2.6  | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 356 | First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211347. | 1.3  | 3         |
| 357 | Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review). <i>Oncology Reports</i> , 2022, 49, .  | 2.6  | 4         |
| 358 | KRAS in NSCLC: State of the Art and Future Perspectives. <i>Cancers</i> , 2022, 14, 5430.   | 3.7  | 18        |
| 359 | Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .  | 2.8  | 3         |
| 360 | Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-4.   | 2.4  | 0         |
| 361 | An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. <i>Frontiers in Immunology</i> , 0, 13, .  | 4.8  | 6         |
| 363 | Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy. <i>Journal of Clinical Pathology</i> , 0, , jcp-2022-208574.   | 2.0  | 0         |
| 364 | Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. , 2022, 10, e005436.   |      | 3         |
| 365 | Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.                                  | 4.1  | 6         |
| 366 | Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. , 2022, 10, e004952.                               |      | 4         |
| 367 | Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. <i>Journal of Hematology and Oncology</i> , 2022, 15, .  | 17.0 | 46        |
| 370 | Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. <i>Biomarker Research</i> , 2023, 11, .   | 6.8  | 8         |
| 371 | Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .  | 3.5  | 2         |
| 372 | Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. <i>Cancers</i> , 2023, 15, 841.  | 3.7  | 15        |
| 373 | Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 187-198.                                      | 2.4  | 3         |
| 374 | Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. <i>Cancer Letters</i> , 2023, 562, 216167.  | 7.2  | 5         |
| 375 | Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. <i>Cancer Treatment Reviews</i> , 2023, 114, 102520.   | 7.7  | 8         |
| 376 | PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer. <i>Lung Cancer</i> , 2023, 178, 1-10.  | 2.0  | 0         |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 377 | Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .       | 2.8  | 0         |
| 378 | The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 157-157.         | 1.7  | 2         |
| 379 | Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 0, , .   | 0.9  | 0         |
| 380 | Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. <i>European Journal of Cancer</i> , 2023, 184, 172-178.                                       | 2.8  | 5         |
| 381 | Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 657-663.  | 1.1  | 21        |
| 382 | Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. <i>Frontiers of Medicine</i> , 2023, 17, 18-42.  | 3.4  | 8         |
| 384 | Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .   | 1.3  | 1         |
| 385 | Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy. <i>Cancer</i> , 2023, 129, 1662-1671.   | 4.1  | 2         |
| 386 | Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. <i>Nature Medicine</i> , 2023, 29, 593-604.   | 30.7 | 46        |
| 387 | Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. , 2023, 11, e006243.   |      | 7         |
| 388 | Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.  | 3.2  | 8         |
| 389 | Mechanism exploration and prognosis study of Astragali Radix-Spreading hedyotis herb for the treatment of lung adenocarcinoma based on bioinformatics approaches and molecular dynamics simulation. <i>Frontiers in Chemistry</i> , 0, 11, . | 3.6  | 2         |
| 390 | The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .  | 2.8  | 2         |
| 391 | Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. <i>World Journal of Cancer Research</i> , 2023, 13, 37-43.   | 0.1  | 0         |
| 392 | Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .   | 8.6  | 5         |
| 393 | Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies. <i>Cancers</i> , 2023, 15, 2665.   | 3.7  | 1         |
| 394 | Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics. <i>BMC Cancer</i> , 2023, 23, .  | 2.6  | 1         |
| 395 | Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .  | 2.0  | 3         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 396 | CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer: Targets and Therapy, 0, Volume 14, 41-46.  | 2.7 | 1         |
| 397 | Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?. Expert Opinion on Therapeutic Targets, 2023, 27, 305-324.   | 3.4 | 7         |
| 398 | Sex Differences in Lung Cancer. Cancers, 2023, 15, 3111.   | 3.7 | 6         |
| 399 | Continuous versus fixed 2-year duration immune checkpoint inhibitor treatment of patients with non-small cell lung cancer: a single institution database analysis. Clinical Lung Cancer, 2023, , .   | 2.6 | 0         |
| 400 | A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer. Journal of Personalized Medicine, 2023, 13, 1010.  | 2.5 | 2         |
| 401 | Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma. Cancers, 2023, 15, 2749.  | 3.7 | 0         |
| 402 | The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?. Lung Cancer, 2023, 181, 107249.   | 2.0 | 2         |
| 403 | Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials. European Journal of Cancer, 2023, 189, 112927.  | 2.8 | 4         |
| 404 | Abnormal activation of <i>NF-<math>\kappa</math>B</i> and <i>MAPK</i> signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment. Thoracic Cancer, 2023, 14, 1843-1856. | 1.9 | 1         |
| 405 | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. Journal of Cancer Research and Clinical Oncology, 2023, 149, 10027-10040.   | 2.5 | 2         |
| 406 | Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression. Journal of Cancer Research and Clinical Oncology, 0, , .  | 2.5 | 0         |
| 407 | Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance. Biological Procedures Online, 2023, 25, .   | 2.9 | 0         |
| 408 | Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?. International Journal of Molecular Sciences, 2023, 24, 12622.   | 4.1 | 3         |
| 409 | Nivolumab as maintenance therapy following platinum-based chemotherapy in <i>EGFR</i> -mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial. Thoracic Cancer, 2023, 14, 3080-3088.   | 1.9 | 0         |
| 410 | Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. Cancer Medicine, 2023, 12, 19460-19470.   | 2.8 | 0         |
| 411 | How single-cell techniques help us look into lung cancer heterogeneity and immunotherapy. Frontiers in Immunology, 0, 14, .  | 4.8 | 0         |
| 412 | Tackling the immunotherapy conundrum: advances and challenges for operable non-small-cell lung cancer treatment. Immunotherapy, 2023, 15, 1415-1428.   | 2.0 | 1         |
| 413 | Disparity in survival benefits of pembrolizumab between Asian and <i>non-Asian</i> patients with advanced cancers: A systematic review and <i>meta-regression</i> analysis. Cancer Medicine, 2023, 12, 20035-20051.  | 2.8 | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 414 | Epidermal growth factor receptorâ€“mutated nonâ€“small cell lung cancer: a clinical approach. , 2024, , 217-252.   |      | 0         |
| 415 | The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treatment and Research Communications, 2023, 37, 100767.                                    | 1.7  | 0         |
| 417 | Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. British Journal of Cancer, 0, , .   | 6.4  | 0         |
| 418 | Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations. Cancers, 2023, 15, 5450.   | 3.7  | 1         |
| 419 | Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients. Biomedicines, 2023, 11, 2916.  | 3.2  | 0         |
| 420 | Molecular pathology of nonâ€“small cell carcinoma. Histopathology, 2024, 84, 50-66.  | 2.9  | 2         |
| 421 | Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations. BMC Pulmonary Medicine, 2023, 23, .   | 2.0  | 0         |
| 422 | Hematopoietic Transcription Factor RUNX1 is Essential for Promoting Macrophageâ€“Myofibroblast Transition in Nonâ€“Smallâ€“Cell Lung Carcinoma. Advanced Science, 0, , .   | 11.2 | 1         |
| 423 | Incidence and risk factors of immuneâ€“related adverse events induced by immune checkpoint inhibitors among older adults with nonâ€“small cell lung cancer. Cancer Medicine, 2024, 13, .   | 2.8  | 0         |
| 424 | Unveiling the role of KRAS in tumor immune microenvironment. Biomedicine and Pharmacotherapy, 2024, 171, 116058.   | 5.6  | 1         |
| 426 | Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment. Experimental Hematology and Oncology, 2024, 13, .  | 5.0  | 0         |
| 427 | Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data. Frontiers in Oncology, 0, 14, .  | 2.8  | 0         |
| 428 | First-line immunotherapy in non-small cell lung cancer: how to select and where to go. Expert Review of Respiratory Medicine, 2023, 17, 1191-1206.   | 2.5  | 0         |
| 429 | Implication of PDâ€“L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PDâ€“1 blockades: A retrospective exploratory study. Oncology Letters, 2024, 27, .  | 1.8  | 0         |
| 430 | Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of Cancer Research and Clinical Oncology, 2024, 150, . | 2.5  | 0         |
| 431 | Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma. International Immunopharmacology, 2024, 129, 111684.  | 3.8  | 0         |
| 432 | Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2024, 16, .  | 3.2  | 0         |
| 433 | Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma. European Journal of Cancer, 2024, 202, 113985.   | 2.8  | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 434 | Impact of smoking cessation duration on lung cancer mortality: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2024, 196, 104323.        | 4.4  | 0         |
| 435 | The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer Patients Treated With Immunotherapy. <i>Cureus</i> , 2024, , .    | 0.5  | 0         |
| 436 | Outcome differences by sex in oncology clinical trials. <i>Nature Communications</i> , 2024, 15, .   | 12.8 | 0         |
| 437 | rs822336 binding to C/EBP $\beta$ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC. <i>Molecular Cancer</i> , 2024, 23, . | 19.2 | 0         |